Oragenics Inc.
OGENOragenics Inc. (OGEN) is a biotechnology company focused on developing innovative vaccines and antibiotics to combat infectious diseases. The company primarily works on probiotics and therapeutic products to address bacterial infections and enhance immune responses, aiming to improve public health outcomes through novel microbial-based solutions.
Company News
Oragenics, Inc. has submitted a clinical trial protocol for regulatory review to the Health and Disability Ethics Committee in New Zealand for its Phase II trial evaluating ONP-002, a proprietary neurosteroid therapy, for the treatment of mild traumatic brain injury or concussion.
Oragenics provides an update on its drug candidate ONP-002 for treating concussion, including positive developments in stability, formulation, and clinical trial preparation. However, the company also discloses non-compliance with NYSE American listing standards.
Oragenics, a biopharmaceutical company, has postponed its 2023 Annual Meeting of Shareholders, previously scheduled for August 26, 2024. The company stated that a new meeting date will be set and communicated in the future.
The device is intended for initial treatment in the acute setting The device is intended for initial treatment in the acute setting
SARASOTA, Fla., June 26, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced the closing of its public offering of 1,100,000 shares of its common stock at an offering price of $1.00 per share.
